PT  - JOURNAL ARTICLE
AU  - Ma, William
AU  - Soulé, Antoine
AU  - Tremblay, Karine
AU  - Rousseau, Simon
AU  - Emad, Amin
TI  - A circulating proteome-informed prognostic model of COVID-19 disease activity that relies on routinely available clinical laboratories
AID  - 10.1101/2022.11.02.22281834
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.11.02.22281834
4099  - http://medrxiv.org/content/early/2023/03/06/2022.11.02.22281834.short
4100  - http://medrxiv.org/content/early/2023/03/06/2022.11.02.22281834.full
AB  - A minority of people infected with SARS-CoV-2 will develop severe COVID-19 disease. To help physicians predict who is more likely to require admission to ICU, we conducted an unsupervised stratification of the circulating proteome that identified six endophenotypes (EPs) among 731 SARS-CoV-2 PCR-positive hospitalized participants in the Biobanque Québécoise de la COVID-19, with varying degrees of disease severity and times to intensive care unit (ICU) admission. One endophenotype, EP6, was associated with a greater proportion of ICU admission, ventilation support, acute respiratory distress syndrome (ARDS) and death. Clinical features of EP6 included increased levels of C-reactive protein, D-dimers, interleukin-6, ferritin, soluble fms-like tyrosine kinase-1, elevated neutrophils, and depleted lymphocytes, whereas another endophenotype (EP5) was associated with cardiovascular complications, congruent with elevated blood biomarkers of cardiovascular disease like N-terminal pro B-type natriuretic peptide (NT-proBNP), Growth Differentiation Factor-15 (GDF-15), and Troponin T. Importantly, a prognostic model solely based on clinical laboratory measurements was developed and validated on 903 patients that generalizes the EPs to new patients recruited across all pandemic waves (2020-2022) and create new opportunities for automated identification of high-risk groups in the clinic. Thus, this novel way to address pathogenesis that leverages detailed phenotypic information but relies on routinely available information in the clinic to favor translation may find applications in other diseases beyond COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was made possible through open sharing of data and samples from the Biobanque Québécoise de la COVID-19, funded by the Fonds de recherche du Québec - Santé, Génome Québec, the Public Health Agency of Canada and, as of March 2022, the Ministère de la Santé et des Services Sociaux du Québec. We thank all participants to BQC19 for their contribution. This study was supported by the Fonds de recherche du Québec - Santé (FRQS)- Cardiometabolic Health, Diabetes and Obesity Research Network (CMDO)- Initiative. This work was also supported by Natural Sciences and Engineering Research Council of Canada (NSERC) grant RGPIN-2019-04460 (AE). The authors also acknowledge the in-kind contribution of Roche Diagnostics, a division of Hoffmann-La Roche Limited, which provided the reagents for the biomarker analyses conducted on the BQC19 blood samples.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Review Board of the Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean (CIUSSS-SLSJ) affiliated to Université de Sherbrooke [protocol #2021-369, 2021-014 CMDO - COVID19].I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInput data corresponding to the cohort can be obtained form BQC19 (www.quebeccovidbiobank.ca). The data generated as a result of the analyses are provided as tables and supplementary tables. https://www.quebeccovidbiobank.ca